NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
Clinical Trials
36 trialsNCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT04889495 2025-03-19
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer
Withdrawn
NCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT05456165 2024-12-31
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Phase 2 Withdrawn
NCT05821582 2023-10-12
Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens
Sanguine Biosciences
Withdrawn
NCT05183295 2023-04-03
Medical Food for the Dietary Management of Metastatic Colorectal Cancer
Faeth Therapeutics
Phase NA Withdrawn
NCT01792882 2023-02-28
GBCPRT0008
Global BioClinical
Withdrawn
NCT05730673 2023-02-17
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
CytoDyn, Inc.
Phase 2 Withdrawn
NCT04632199 2022-08-24
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
Ipsen
Phase 1 Withdrawn
NCT03682744 2022-04-06
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT01915472 2021-08-19
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 2 Withdrawn
NCT01273402 2021-08-16
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 1 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT04195373 2020-11-25
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Themis Bioscience GmbH
Phase 1 Withdrawn
NCT04145193 2020-09-21
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Phase 2 Withdrawn
NCT03448874 2020-07-30
SEALAR
Sealantis Ltd.
Phase NA Withdrawn
NCT04285008 2020-06-25
RESCue
Motus GI Medical Technologies Ltd
Phase NA Withdrawn
NCT03688230 2020-03-18
AMELION
SFJ Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01741038 2020-01-22
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
Mirror Biologics, Inc.
Phase 2/3 Withdrawn
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn
NCT03493009 2018-10-31
Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System
Motus GI Medical Technologies Ltd
Phase NA Withdrawn
NCT00577109 2018-07-31
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Withdrawn
NCT00388700 2018-02-14
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT02542436 2017-09-13
Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population
Hoffmann-La Roche
Withdrawn
NCT00510627 2017-03-03
Prometheus
Boston Scientific Corporation
Phase 4 Withdrawn
NCT02423174 2017-02-10
Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery
Domain Surgical, Inc.
Withdrawn
NCT02965417 2017-02-01
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Symphogen A/S
Phase 2 Withdrawn
NCT02785068 2017-01-11
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Merrimack Pharmaceuticals
Phase 1/2 Withdrawn
NCT01338558 2016-11-02
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
Hoffmann-La Roche
Phase 3 Withdrawn
NCT00735241 2015-05-22
FAST
Sirtex Medical
Phase 2/3 Withdrawn
NCT01574677 2014-08-04
Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test
Epigenomics, Inc
Withdrawn
NCT00233623 2011-01-27
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
AstraZeneca
Phase 2 Withdrawn
NCT00988897 2009-12-23
Colorectal Cancer RECHALLENGE
Sanofi
Phase 2 Withdrawn